nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—lung cancer	0.163	1	CtDrD
Vandetanib—Erlotinib—lung cancer	0.133	0.529	CrCtD
Vandetanib—Gefitinib—lung cancer	0.119	0.471	CrCtD
Vandetanib—Erlotinib—Gefitinib—lung cancer	0.0475	0.297	CrCrCtD
Vandetanib—Afatinib—Gefitinib—lung cancer	0.0475	0.297	CrCrCtD
Vandetanib—Bosutinib—Gefitinib—lung cancer	0.0475	0.297	CrCrCtD
Vandetanib—AXL—lung cancer	0.0351	0.243	CbGaD
Vandetanib—FGR—lung cancer	0.0299	0.206	CbGaD
Vandetanib—ERBB3—lung cancer	0.0213	0.147	CbGaD
Vandetanib—Gefitinib—Erlotinib—lung cancer	0.0176	0.11	CrCrCtD
Vandetanib—SRC—lung cancer	0.0142	0.0981	CbGaD
Vandetanib—KDR—lung cancer	0.0133	0.0922	CbGaD
Vandetanib—VEGFA—lung cancer	0.0113	0.0782	CbGaD
Vandetanib—EGFR—lung cancer	0.00954	0.066	CbGaD
Vandetanib—MKNK1—Gefitinib—lung cancer	0.00801	0.0418	CbGbCtD
Vandetanib—ERBB3—Gefitinib—lung cancer	0.00801	0.0418	CbGbCtD
Vandetanib—IRAK4—Gefitinib—lung cancer	0.00801	0.0418	CbGbCtD
Vandetanib—ABCG2—lung cancer	0.00697	0.0482	CbGaD
Vandetanib—RIPK2—Crizotinib—lung cancer	0.00618	0.0323	CbGbCtD
Vandetanib—EPHA6—Gefitinib—lung cancer	0.00512	0.0267	CbGbCtD
Vandetanib—TYRO3—Crizotinib—lung cancer	0.00491	0.0256	CbGbCtD
Vandetanib—EPHA5—Crizotinib—lung cancer	0.00491	0.0256	CbGbCtD
Vandetanib—STK35—Crizotinib—lung cancer	0.00491	0.0256	CbGbCtD
Vandetanib—AXL—Crizotinib—lung cancer	0.00491	0.0256	CbGbCtD
Vandetanib—LTK—Crizotinib—lung cancer	0.00491	0.0256	CbGbCtD
Vandetanib—BMPR1B—Crizotinib—lung cancer	0.00491	0.0256	CbGbCtD
Vandetanib—MKNK1—Erlotinib—lung cancer	0.00474	0.0247	CbGbCtD
Vandetanib—LTK—Erlotinib—lung cancer	0.00474	0.0247	CbGbCtD
Vandetanib—EGFR—Gefitinib—lung cancer	0.0046	0.024	CbGbCtD
Vandetanib—STK10—Gefitinib—lung cancer	0.0046	0.024	CbGbCtD
Vandetanib—MAP2K5—Gefitinib—lung cancer	0.00419	0.0219	CbGbCtD
Vandetanib—TEK—Crizotinib—lung cancer	0.00411	0.0214	CbGbCtD
Vandetanib—EPHA8—Crizotinib—lung cancer	0.00411	0.0214	CbGbCtD
Vandetanib—SLK—Crizotinib—lung cancer	0.00411	0.0214	CbGbCtD
Vandetanib—MAP4K5—Crizotinib—lung cancer	0.00411	0.0214	CbGbCtD
Vandetanib—PLK4—Crizotinib—lung cancer	0.00411	0.0214	CbGbCtD
Vandetanib—YES1—Crizotinib—lung cancer	0.00411	0.0214	CbGbCtD
Vandetanib—SLK—Erlotinib—lung cancer	0.00396	0.0207	CbGbCtD
Vandetanib—MAP3K19—Gefitinib—lung cancer	0.00385	0.0201	CbGbCtD
Vandetanib—FLT3—Crizotinib—lung cancer	0.00355	0.0185	CbGbCtD
Vandetanib—FGR—Crizotinib—lung cancer	0.00355	0.0185	CbGbCtD
Vandetanib—FLT3—Erlotinib—lung cancer	0.00342	0.0179	CbGbCtD
Vandetanib—SRC—Crizotinib—lung cancer	0.00314	0.0164	CbGbCtD
Vandetanib—BLK—Crizotinib—lung cancer	0.00314	0.0164	CbGbCtD
Vandetanib—EPHA6—Crizotinib—lung cancer	0.00314	0.0164	CbGbCtD
Vandetanib—EPHB6—Crizotinib—lung cancer	0.00314	0.0164	CbGbCtD
Vandetanib—LYN—Crizotinib—lung cancer	0.00314	0.0164	CbGbCtD
Vandetanib—ALB—lung cancer	0.00304	0.021	CbGaD
Vandetanib—EPHA6—Erlotinib—lung cancer	0.00303	0.0158	CbGbCtD
Vandetanib—STK10—Crizotinib—lung cancer	0.00282	0.0147	CbGbCtD
Vandetanib—ABL2—Crizotinib—lung cancer	0.00282	0.0147	CbGbCtD
Vandetanib—EGFR—Erlotinib—lung cancer	0.00272	0.0142	CbGbCtD
Vandetanib—ABL2—Erlotinib—lung cancer	0.00272	0.0142	CbGbCtD
Vandetanib—STK10—Erlotinib—lung cancer	0.00272	0.0142	CbGbCtD
Vandetanib—LCK—Crizotinib—lung cancer	0.00257	0.0134	CbGbCtD
Vandetanib—MAP2K5—Erlotinib—lung cancer	0.00248	0.0129	CbGbCtD
Vandetanib—MAP3K19—Crizotinib—lung cancer	0.00236	0.0123	CbGbCtD
Vandetanib—MAP3K19—Erlotinib—lung cancer	0.00228	0.0119	CbGbCtD
Vandetanib—ABL1—Crizotinib—lung cancer	0.00204	0.0106	CbGbCtD
Vandetanib—ABL1—Erlotinib—lung cancer	0.00197	0.0103	CbGbCtD
Vandetanib—EGFR—Docetaxel—lung cancer	0.0018	0.0094	CbGbCtD
Vandetanib—ORM1—Gefitinib—lung cancer	0.00124	0.0065	CbGbCtD
Vandetanib—ABCG2—Topotecan—lung cancer	0.000831	0.00434	CbGbCtD
Vandetanib—ABCG2—Gefitinib—lung cancer	0.00076	0.00397	CbGbCtD
Vandetanib—ABCG2—Teniposide—lung cancer	0.000737	0.00385	CbGbCtD
Vandetanib—ORM1—Erlotinib—lung cancer	0.000736	0.00384	CbGbCtD
Vandetanib—ABCC1—Paclitaxel—lung cancer	0.000614	0.00321	CbGbCtD
Vandetanib—ABCC1—Irinotecan—lung cancer	0.000606	0.00317	CbGbCtD
Vandetanib—ABCC1—Vinblastine—lung cancer	0.000539	0.00281	CbGbCtD
Vandetanib—ALB—Gefitinib—lung cancer	0.000524	0.00273	CbGbCtD
Vandetanib—ABCC1—Etoposide—lung cancer	0.000486	0.00254	CbGbCtD
Vandetanib—ABCG2—Erlotinib—lung cancer	0.000449	0.00235	CbGbCtD
Vandetanib—ABCC1—Docetaxel—lung cancer	0.000444	0.00232	CbGbCtD
Vandetanib—ABCG2—Paclitaxel—lung cancer	0.000411	0.00215	CbGbCtD
Vandetanib—ABCG2—Irinotecan—lung cancer	0.000406	0.00212	CbGbCtD
Vandetanib—KDR—umbilical vein—lung cancer	0.0004	0.0235	CbGeAlD
Vandetanib—ABCC1—Doxorubicin—lung cancer	0.000331	0.00173	CbGbCtD
Vandetanib—ABCG2—Cisplatin—lung cancer	0.000331	0.00173	CbGbCtD
Vandetanib—ABCG2—Etoposide—lung cancer	0.000325	0.0017	CbGbCtD
Vandetanib—ABCC1—Methotrexate—lung cancer	0.000321	0.00168	CbGbCtD
Vandetanib—ALB—Erlotinib—lung cancer	0.00031	0.00162	CbGbCtD
Vandetanib—ABCG2—Docetaxel—lung cancer	0.000297	0.00155	CbGbCtD
Vandetanib—ALB—Irinotecan—lung cancer	0.00028	0.00146	CbGbCtD
Vandetanib—EGFR—mammary gland—lung cancer	0.000238	0.014	CbGeAlD
Vandetanib—FMO1—mammary gland—lung cancer	0.000229	0.0134	CbGeAlD
Vandetanib—ABCG2—Doxorubicin—lung cancer	0.000222	0.00116	CbGbCtD
Vandetanib—ERBB3—mammary gland—lung cancer	0.000221	0.013	CbGeAlD
Vandetanib—ABCG2—Methotrexate—lung cancer	0.000215	0.00112	CbGbCtD
Vandetanib—PLK4—respiratory system—lung cancer	0.000213	0.0125	CbGeAlD
Vandetanib—PTK6—bronchus—lung cancer	0.000213	0.0125	CbGeAlD
Vandetanib—MKNK1—mammary gland—lung cancer	0.000208	0.0122	CbGeAlD
Vandetanib—RET—mammary gland—lung cancer	0.000205	0.012	CbGeAlD
Vandetanib—AXL—mammary gland—lung cancer	0.000204	0.012	CbGeAlD
Vandetanib—SLK—mammary gland—lung cancer	0.000197	0.0115	CbGeAlD
Vandetanib—MAP3K19—respiratory system—lung cancer	0.000196	0.0115	CbGeAlD
Vandetanib—PTK6—trachea—lung cancer	0.000191	0.0112	CbGeAlD
Vandetanib—TEK—mammary gland—lung cancer	0.000187	0.011	CbGeAlD
Vandetanib—CYP3A4—Topotecan—lung cancer	0.000179	0.000937	CbGbCtD
Vandetanib—YES1—mammary gland—lung cancer	0.000173	0.0101	CbGeAlD
Vandetanib—FLT3—respiratory system—lung cancer	0.00017	0.01	CbGeAlD
Vandetanib—CYP3A4—Gefitinib—lung cancer	0.000164	0.000857	CbGbCtD
Vandetanib—BMPR1B—epithelium—lung cancer	0.000164	0.00963	CbGeAlD
Vandetanib—BMPR1B—bronchus—lung cancer	0.000162	0.00948	CbGeAlD
Vandetanib—CYP3A4—Teniposide—lung cancer	0.000159	0.000831	CbGbCtD
Vandetanib—FLT4—respiratory system—lung cancer	0.000155	0.00908	CbGeAlD
Vandetanib—KDR—mammary gland—lung cancer	0.000153	0.00896	CbGeAlD
Vandetanib—Afatinib—ERBB2—lung cancer	0.000148	0.113	CrCbGaD
Vandetanib—ALB—Methotrexate—lung cancer	0.000148	0.000773	CbGbCtD
Vandetanib—ERBB3—respiratory system—lung cancer	0.000147	0.00865	CbGeAlD
Vandetanib—LTK—lung—lung cancer	0.000144	0.00842	CbGeAlD
Vandetanib—PTK6—lung—lung cancer	0.000138	0.00807	CbGeAlD
Vandetanib—FGR—respiratory system—lung cancer	0.000137	0.00802	CbGeAlD
Vandetanib—AXL—respiratory system—lung cancer	0.000136	0.00799	CbGeAlD
Vandetanib—PDGFRB—mammary gland—lung cancer	0.000132	0.00775	CbGeAlD
Vandetanib—FMO3—respiratory system—lung cancer	0.000132	0.00775	CbGeAlD
Vandetanib—FLT4—epithelium—lung cancer	0.000129	0.00759	CbGeAlD
Vandetanib—RIPK2—epithelium—lung cancer	0.000129	0.00755	CbGeAlD
Vandetanib—FYN—respiratory system—lung cancer	0.000127	0.00748	CbGeAlD
Vandetanib—RIPK2—bronchus—lung cancer	0.000127	0.00744	CbGeAlD
Vandetanib—CYP3A4—Vinorelbine—lung cancer	0.000126	0.00066	CbGbCtD
Vandetanib—VEGFA—bronchus—lung cancer	0.000126	0.00742	CbGeAlD
Vandetanib—Bosutinib—TXK—lung cancer	0.000126	0.0962	CrCbGaD
Vandetanib—PLK4—bone marrow—lung cancer	0.000125	0.00734	CbGeAlD
Vandetanib—TEK—respiratory system—lung cancer	0.000124	0.00731	CbGeAlD
Vandetanib—IRAK4—bronchus—lung cancer	0.000124	0.00726	CbGeAlD
Vandetanib—ERBB3—epithelium—lung cancer	0.000123	0.00723	CbGeAlD
Vandetanib—ABL1—mammary gland—lung cancer	0.000118	0.00691	CbGeAlD
Vandetanib—STK35—cardiac atrium—lung cancer	0.000116	0.0068	CbGeAlD
Vandetanib—YES1—respiratory system—lung cancer	0.000115	0.00675	CbGeAlD
Vandetanib—RET—epithelium—lung cancer	0.000114	0.0067	CbGeAlD
Vandetanib—STK10—respiratory system—lung cancer	0.000114	0.00669	CbGeAlD
Vandetanib—MKNK1—bronchus—lung cancer	0.000114	0.00668	CbGeAlD
Vandetanib—RIPK2—trachea—lung cancer	0.000114	0.00668	CbGeAlD
Vandetanib—VEGFA—trachea—lung cancer	0.000113	0.00666	CbGeAlD
Vandetanib—PLK4—lung—lung cancer	0.000113	0.00665	CbGeAlD
Vandetanib—FMO1—trachea—lung cancer	0.000113	0.00662	CbGeAlD
Vandetanib—LCK—bronchus—lung cancer	0.000112	0.0066	CbGeAlD
Vandetanib—Bosutinib—AXL—lung cancer	0.000112	0.0857	CrCbGaD
Vandetanib—IRAK4—trachea—lung cancer	0.000111	0.00652	CbGeAlD
Vandetanib—SRC—respiratory system—lung cancer	0.000111	0.00649	CbGeAlD
Vandetanib—ERBB3—trachea—lung cancer	0.000109	0.00639	CbGeAlD
Vandetanib—ALB—mammary gland—lung cancer	0.000109	0.00638	CbGeAlD
Vandetanib—FMO3—bronchus—lung cancer	0.000109	0.00637	CbGeAlD
Vandetanib—SLK—bronchus—lung cancer	0.000108	0.00633	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—lung cancer	0.000107	0.00627	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—lung cancer	0.000107	0.00625	CbGeAlD
Vandetanib—PLK4—Topotecan—Irinotecan—lung cancer	0.000106	0.157	CbGdCrCtD
Vandetanib—PLK4—Etoposide—Teniposide—lung cancer	0.000105	0.156	CbGdCrCtD
Vandetanib—ERBB3—Podofilox—Teniposide—lung cancer	0.000105	0.156	CbGdCrCtD
Vandetanib—FYN—bronchus—lung cancer	0.000105	0.00615	CbGeAlD
Vandetanib—BMPR1B—lung—lung cancer	0.000104	0.00612	CbGeAlD
Vandetanib—MAP3K19—lung—lung cancer	0.000104	0.00612	CbGeAlD
Vandetanib—TEK—epithelium—lung cancer	0.000104	0.00611	CbGeAlD
Vandetanib—TEK—bronchus—lung cancer	0.000102	0.00601	CbGeAlD
Vandetanib—MAP4K5—bronchus—lung cancer	0.000102	0.00601	CbGeAlD
Vandetanib—KDR—respiratory system—lung cancer	0.000102	0.00597	CbGeAlD
Vandetanib—LCK—trachea—lung cancer	0.000101	0.00593	CbGeAlD
Vandetanib—CYP3A4—Crizotinib—lung cancer	0.000101	0.000525	CbGbCtD
Vandetanib—AXL—trachea—lung cancer	0.000101	0.0059	CbGeAlD
Vandetanib—FLT3—bone marrow—lung cancer	9.99e-05	0.00586	CbGeAlD
Vandetanib—BLK—lymph node—lung cancer	9.93e-05	0.00582	CbGeAlD
Vandetanib—LTK—lymph node—lung cancer	9.81e-05	0.00576	CbGeAlD
Vandetanib—EPHB6—bronchus—lung cancer	9.79e-05	0.00575	CbGeAlD
Vandetanib—CYP3A4—Erlotinib—lung cancer	9.7e-05	0.000507	CbGbCtD
Vandetanib—SLK—trachea—lung cancer	9.68e-05	0.00568	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—lung cancer	9.6e-05	0.00564	CbGeAlD
Vandetanib—Bosutinib—MAP2K1—lung cancer	9.54e-05	0.0729	CrCbGaD
Vandetanib—Bosutinib—FGR—lung cancer	9.54e-05	0.0729	CrCbGaD
Vandetanib—YES1—bronchus—lung cancer	9.46e-05	0.00555	CbGeAlD
Vandetanib—AXL—cardiac atrium—lung cancer	9.45e-05	0.00554	CbGeAlD
Vandetanib—FYN—trachea—lung cancer	9.41e-05	0.00552	CbGeAlD
Vandetanib—STK10—bronchus—lung cancer	9.38e-05	0.0055	CbGeAlD
Vandetanib—SRC—epithelium—lung cancer	9.24e-05	0.00542	CbGeAlD
Vandetanib—MAP4K5—trachea—lung cancer	9.2e-05	0.0054	CbGeAlD
Vandetanib—SLK—cardiac atrium—lung cancer	9.1e-05	0.00534	CbGeAlD
Vandetanib—FLT4—bone marrow—lung cancer	9.07e-05	0.00532	CbGeAlD
Vandetanib—FLT3—lung—lung cancer	9.05e-05	0.00531	CbGeAlD
Vandetanib—RIPK2—bone marrow—lung cancer	9.02e-05	0.00529	CbGeAlD
Vandetanib—VEGFA—bone marrow—lung cancer	9e-05	0.00528	CbGeAlD
Vandetanib—ABL1—Topotecan—Irinotecan—lung cancer	8.92e-05	0.132	CbGdCrCtD
Vandetanib—CYP3A4—Paclitaxel—lung cancer	8.88e-05	0.000464	CbGbCtD
Vandetanib—STK35—lung—lung cancer	8.87e-05	0.0052	CbGeAlD
Vandetanib—FYN—cardiac atrium—lung cancer	8.84e-05	0.00519	CbGeAlD
Vandetanib—IRAK4—bone marrow—lung cancer	8.81e-05	0.00517	CbGeAlD
Vandetanib—PDGFRB—respiratory system—lung cancer	8.81e-05	0.00517	CbGeAlD
Vandetanib—EPHB6—trachea—lung cancer	8.79e-05	0.00516	CbGeAlD
Vandetanib—CYP3A4—Irinotecan—lung cancer	8.76e-05	0.000458	CbGbCtD
Vandetanib—MAP4K5—cardiac atrium—lung cancer	8.64e-05	0.00507	CbGeAlD
Vandetanib—TEK—cardiac atrium—lung cancer	8.64e-05	0.00507	CbGeAlD
Vandetanib—ABL2—lung—lung cancer	8.64e-05	0.00507	CbGeAlD
Vandetanib—KDR—epithelium—lung cancer	8.5e-05	0.00499	CbGeAlD
Vandetanib—YES1—trachea—lung cancer	8.5e-05	0.00499	CbGeAlD
Vandetanib—EGFR—lung—lung cancer	8.43e-05	0.00495	CbGeAlD
Vandetanib—KDR—bronchus—lung cancer	8.37e-05	0.00491	CbGeAlD
Vandetanib—MAP2K5—bronchus—lung cancer	8.37e-05	0.00491	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—lung cancer	8.26e-05	0.00485	CbGeAlD
Vandetanib—FLT4—lung—lung cancer	8.22e-05	0.00482	CbGeAlD
Vandetanib—RIPK2—lung—lung cancer	8.17e-05	0.0048	CbGeAlD
Vandetanib—VEGFA—lung—lung cancer	8.15e-05	0.00478	CbGeAlD
Vandetanib—FMO1—lung—lung cancer	8.11e-05	0.00476	CbGeAlD
Vandetanib—MKNK1—bone marrow—lung cancer	8.11e-05	0.00476	CbGeAlD
Vandetanib—LCK—bone marrow—lung cancer	8.01e-05	0.0047	CbGeAlD
Vandetanib—FGR—bone marrow—lung cancer	8.01e-05	0.0047	CbGeAlD
Vandetanib—IRAK4—lung—lung cancer	7.98e-05	0.00468	CbGeAlD
Vandetanib—YES1—cardiac atrium—lung cancer	7.98e-05	0.00468	CbGeAlD
Vandetanib—ABL1—respiratory system—lung cancer	7.85e-05	0.00461	CbGeAlD
Vandetanib—ERBB3—lung—lung cancer	7.82e-05	0.00459	CbGeAlD
Vandetanib—CYP3A4—Vinblastine—lung cancer	7.79e-05	0.000407	CbGbCtD
Vandetanib—PLK4—lymph node—lung cancer	7.75e-05	0.00455	CbGeAlD
Vandetanib—SLK—bone marrow—lung cancer	7.68e-05	0.00451	CbGeAlD
Vandetanib—SRC—cardiac atrium—lung cancer	7.68e-05	0.00451	CbGeAlD
Vandetanib—KDR—trachea—lung cancer	7.52e-05	0.00441	CbGeAlD
Vandetanib—MAP2K5—trachea—lung cancer	7.52e-05	0.00441	CbGeAlD
Vandetanib—FYN—bone marrow—lung cancer	7.47e-05	0.00438	CbGeAlD
Vandetanib—PDGFRB—epithelium—lung cancer	7.36e-05	0.00432	CbGeAlD
Vandetanib—MKNK1—lung—lung cancer	7.35e-05	0.00431	CbGeAlD
Vandetanib—MAP4K5—bone marrow—lung cancer	7.3e-05	0.00428	CbGeAlD
Vandetanib—LCK—lung—lung cancer	7.26e-05	0.00426	CbGeAlD
Vandetanib—FGR—lung—lung cancer	7.26e-05	0.00426	CbGeAlD
Vandetanib—PDGFRB—bronchus—lung cancer	7.25e-05	0.00425	CbGeAlD
Vandetanib—AXL—lung—lung cancer	7.23e-05	0.00424	CbGeAlD
Vandetanib—BMPR1B—lymph node—lung cancer	7.13e-05	0.00418	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—lung cancer	7.06e-05	0.00414	CbGeAlD
Vandetanib—KDR—cardiac atrium—lung cancer	7.06e-05	0.00414	CbGeAlD
Vandetanib—CYP3A4—Etoposide—lung cancer	7.02e-05	0.000367	CbGbCtD
Vandetanib—FMO3—lung—lung cancer	7.01e-05	0.00411	CbGeAlD
Vandetanib—Afatinib—EGFR—lung cancer	7.01e-05	0.0535	CrCbGaD
Vandetanib—SLK—lung—lung cancer	6.96e-05	0.00408	CbGeAlD
Vandetanib—Gefitinib—ERBB3—lung cancer	6.91e-05	0.0527	CrCbGaD
Vandetanib—Bosutinib—ERBB3—lung cancer	6.8e-05	0.0519	CrCbGaD
Vandetanib—Bosutinib—ALK—lung cancer	6.8e-05	0.0519	CrCbGaD
Vandetanib—FYN—lung—lung cancer	6.76e-05	0.00397	CbGeAlD
Vandetanib—YES1—bone marrow—lung cancer	6.74e-05	0.00395	CbGeAlD
Vandetanib—STK10—bone marrow—lung cancer	6.68e-05	0.00392	CbGeAlD
Vandetanib—TEK—lung—lung cancer	6.61e-05	0.00388	CbGeAlD
Vandetanib—MAP4K5—lung—lung cancer	6.61e-05	0.00388	CbGeAlD
Vandetanib—PDGFRB—trachea—lung cancer	6.51e-05	0.00382	CbGeAlD
Vandetanib—ABL1—bronchus—lung cancer	6.46e-05	0.00379	CbGeAlD
Vandetanib—Erlotinib—UGT1A1—lung cancer	6.43e-05	0.0491	CrCbGaD
Vandetanib—CYP3A4—Docetaxel—lung cancer	6.42e-05	0.000335	CbGbCtD
Vandetanib—EPHB6—lung—lung cancer	6.32e-05	0.00371	CbGeAlD
Vandetanib—ERBB3—Podofilox—Etoposide—lung cancer	6.24e-05	0.0926	CbGdCrCtD
Vandetanib—FLT3—lymph node—lung cancer	6.19e-05	0.00363	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—lung cancer	6.11e-05	0.00359	CbGeAlD
Vandetanib—YES1—lung—lung cancer	6.1e-05	0.00358	CbGeAlD
Vandetanib—STK35—lymph node—lung cancer	6.06e-05	0.00356	CbGeAlD
Vandetanib—STK10—lung—lung cancer	6.05e-05	0.00355	CbGeAlD
Vandetanib—KDR—bone marrow—lung cancer	5.96e-05	0.0035	CbGeAlD
Vandetanib—ABL2—lymph node—lung cancer	5.91e-05	0.00347	CbGeAlD
Vandetanib—SRC—lung—lung cancer	5.87e-05	0.00345	CbGeAlD
Vandetanib—ABL1—trachea—lung cancer	5.8e-05	0.0034	CbGeAlD
Vandetanib—EGFR—lymph node—lung cancer	5.77e-05	0.00338	CbGeAlD
Vandetanib—FLT4—lymph node—lung cancer	5.62e-05	0.0033	CbGeAlD
Vandetanib—RIPK2—lymph node—lung cancer	5.59e-05	0.00328	CbGeAlD
Vandetanib—VEGFA—lymph node—lung cancer	5.58e-05	0.00327	CbGeAlD
Vandetanib—FMO1—lymph node—lung cancer	5.55e-05	0.00325	CbGeAlD
Vandetanib—IRAK4—lymph node—lung cancer	5.46e-05	0.0032	CbGeAlD
Vandetanib—ABL1—cardiac atrium—lung cancer	5.45e-05	0.0032	CbGeAlD
Vandetanib—KDR—lung—lung cancer	5.4e-05	0.00317	CbGeAlD
Vandetanib—MAP2K5—lung—lung cancer	5.4e-05	0.00317	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vinorelbine—lung cancer	5.37e-05	0.0797	CbGdCrCtD
Vandetanib—ERBB3—lymph node—lung cancer	5.35e-05	0.00314	CbGeAlD
Vandetanib—PDGFRB—bone marrow—lung cancer	5.16e-05	0.00303	CbGeAlD
Vandetanib—Afatinib—ABCG2—lung cancer	5.12e-05	0.0391	CrCbGaD
Vandetanib—MKNK1—lymph node—lung cancer	5.02e-05	0.00295	CbGeAlD
Vandetanib—RET—lymph node—lung cancer	4.96e-05	0.00291	CbGeAlD
Vandetanib—LCK—lymph node—lung cancer	4.96e-05	0.00291	CbGeAlD
Vandetanib—FGR—lymph node—lung cancer	4.96e-05	0.00291	CbGeAlD
Vandetanib—Erlotinib—EGFR—lung cancer	4.95e-05	0.0378	CrCbGaD
Vandetanib—AXL—lymph node—lung cancer	4.94e-05	0.0029	CbGeAlD
Vandetanib—ABCC1—bronchus—lung cancer	4.92e-05	0.00289	CbGeAlD
Vandetanib—ORM1—bone marrow—lung cancer	4.84e-05	0.00284	CbGeAlD
Vandetanib—FMO3—lymph node—lung cancer	4.79e-05	0.00281	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—lung cancer	4.79e-05	0.00025	CbGbCtD
Vandetanib—PLK4—Teniposide—Etoposide—lung cancer	4.78e-05	0.0709	CbGdCrCtD
Vandetanib—SLK—lymph node—lung cancer	4.76e-05	0.00279	CbGeAlD
Vandetanib—PDGFRB—lung—lung cancer	4.68e-05	0.00274	CbGeAlD
Vandetanib—FYN—lymph node—lung cancer	4.63e-05	0.00271	CbGeAlD
Vandetanib—ABL1—bone marrow—lung cancer	4.6e-05	0.0027	CbGeAlD
Vandetanib—Bosutinib—SRC—lung cancer	4.54e-05	0.0346	CrCbGaD
Vandetanib—MAP4K5—lymph node—lung cancer	4.52e-05	0.00265	CbGeAlD
Vandetanib—TEK—lymph node—lung cancer	4.52e-05	0.00265	CbGeAlD
Vandetanib—ABCC1—trachea—lung cancer	4.42e-05	0.00259	CbGeAlD
Vandetanib—ORM1—lung—lung cancer	4.39e-05	0.00257	CbGeAlD
Vandetanib—EPHB6—lymph node—lung cancer	4.32e-05	0.00254	CbGeAlD
Vandetanib—YES1—lymph node—lung cancer	4.18e-05	0.00245	CbGeAlD
Vandetanib—ABL1—lung—lung cancer	4.17e-05	0.00245	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—lung cancer	4.15e-05	0.00244	CbGeAlD
Vandetanib—STK10—lymph node—lung cancer	4.14e-05	0.00243	CbGeAlD
Vandetanib—SRC—lymph node—lung cancer	4.02e-05	0.00236	CbGeAlD
Vandetanib—MAP2K5—lymph node—lung cancer	3.69e-05	0.00217	CbGeAlD
Vandetanib—KDR—lymph node—lung cancer	3.69e-05	0.00217	CbGeAlD
Vandetanib—Erlotinib—ABCG2—lung cancer	3.61e-05	0.0276	CrCbGaD
Vandetanib—PDGFRB—lymph node—lung cancer	3.2e-05	0.00188	CbGeAlD
Vandetanib—ABCC1—lung—lung cancer	3.17e-05	0.00186	CbGeAlD
Vandetanib—Gefitinib—EGFR—lung cancer	3.1e-05	0.0237	CrCbGaD
Vandetanib—Bosutinib—EGFR—lung cancer	3.05e-05	0.0233	CrCbGaD
Vandetanib—ORM1—lymph node—lung cancer	3e-05	0.00176	CbGeAlD
Vandetanib—ABCG2—bone marrow—lung cancer	2.9e-05	0.0017	CbGeAlD
Vandetanib—ABL1—lymph node—lung cancer	2.85e-05	0.00167	CbGeAlD
Vandetanib—Erlotinib—CYP1A1—lung cancer	2.83e-05	0.0216	CrCbGaD
Vandetanib—ALB—lymph node—lung cancer	2.63e-05	0.00154	CbGeAlD
Vandetanib—ABCG2—lung—lung cancer	2.63e-05	0.00154	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—lung cancer	2.31e-05	0.0342	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—lung cancer	2.31e-05	0.0342	CbGdCrCtD
Vandetanib—Gefitinib—ABCG2—lung cancer	2.26e-05	0.0173	CrCbGaD
Vandetanib—ABCC1—lymph node—lung cancer	2.17e-05	0.00127	CbGeAlD
Vandetanib—Afatinib—ABCB1—lung cancer	2.13e-05	0.0163	CrCbGaD
Vandetanib—ABL1—Epirubicin—Doxorubicin—lung cancer	1.94e-05	0.0288	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—lung cancer	1.94e-05	0.0288	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—lung cancer	1.94e-05	0.0288	CbGdCrCtD
Vandetanib—ABCG2—lymph node—lung cancer	1.8e-05	0.00105	CbGeAlD
Vandetanib—Gefitinib—CYP1A1—lung cancer	1.77e-05	0.0135	CrCbGaD
Vandetanib—Erlotinib—ALB—lung cancer	1.58e-05	0.012	CrCbGaD
Vandetanib—Erlotinib—ABCB1—lung cancer	1.5e-05	0.0115	CrCbGaD
Vandetanib—Photosensitivity reaction—Methotrexate—lung cancer	1.14e-05	0.000365	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—lung cancer	1.13e-05	0.000365	CcSEcCtD
Vandetanib—Thrombocytopenia—Paclitaxel—lung cancer	1.13e-05	0.000364	CcSEcCtD
Vandetanib—Skin disorder—Paclitaxel—lung cancer	1.13e-05	0.000362	CcSEcCtD
Vandetanib—Body temperature increased—Irinotecan—lung cancer	1.12e-05	0.000361	CcSEcCtD
Vandetanib—Abdominal pain—Irinotecan—lung cancer	1.12e-05	0.000361	CcSEcCtD
Vandetanib—Decreased appetite—Cisplatin—lung cancer	1.12e-05	0.00036	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—lung cancer	1.12e-05	0.000359	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—lung cancer	1.11e-05	0.000358	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Cisplatin—lung cancer	1.11e-05	0.000358	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—lung cancer	1.11e-05	0.000357	CcSEcCtD
Vandetanib—Infestation—Methotrexate—lung cancer	1.11e-05	0.000357	CcSEcCtD
Vandetanib—Depression—Methotrexate—lung cancer	1.11e-05	0.000355	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—lung cancer	1.1e-05	0.000355	CcSEcCtD
Vandetanib—Pain—Cisplatin—lung cancer	1.1e-05	0.000354	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—lung cancer	1.1e-05	0.000353	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—lung cancer	1.1e-05	0.000353	CcSEcCtD
Vandetanib—Vomiting—Vinorelbine—lung cancer	1.09e-05	0.000352	CcSEcCtD
Vandetanib—Body temperature increased—Gemcitabine—lung cancer	1.09e-05	0.000351	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—lung cancer	1.09e-05	0.00035	CcSEcCtD
Vandetanib—Rash—Vinorelbine—lung cancer	1.09e-05	0.000349	CcSEcCtD
Vandetanib—Dermatitis—Vinorelbine—lung cancer	1.08e-05	0.000349	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—lung cancer	1.08e-05	0.000348	CcSEcCtD
Vandetanib—Headache—Vinorelbine—lung cancer	1.08e-05	0.000347	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—lung cancer	1.08e-05	0.000347	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—lung cancer	1.08e-05	0.000346	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—lung cancer	1.08e-05	0.000346	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—lung cancer	1.06e-05	0.000341	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—lung cancer	1.06e-05	0.00034	CcSEcCtD
Vandetanib—Loss of consciousness—Docetaxel—lung cancer	1.06e-05	0.00034	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—lung cancer	1.06e-05	0.000339	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Paclitaxel—lung cancer	1.06e-05	0.000339	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—lung cancer	1.05e-05	0.000338	CcSEcCtD
Vandetanib—Cough—Docetaxel—lung cancer	1.05e-05	0.000337	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—lung cancer	1.05e-05	0.000337	CcSEcCtD
Vandetanib—Insomnia—Paclitaxel—lung cancer	1.05e-05	0.000337	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—lung cancer	1.05e-05	0.000336	CcSEcCtD
Vandetanib—Convulsion—Docetaxel—lung cancer	1.04e-05	0.000335	CcSEcCtD
Vandetanib—Paraesthesia—Paclitaxel—lung cancer	1.04e-05	0.000334	CcSEcCtD
Vandetanib—Hypertension—Docetaxel—lung cancer	1.04e-05	0.000334	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—lung cancer	1.04e-05	0.000333	CcSEcCtD
Vandetanib—Dyspnoea—Paclitaxel—lung cancer	1.03e-05	0.000332	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—lung cancer	1.03e-05	0.00033	CcSEcCtD
Vandetanib—Arthralgia—Docetaxel—lung cancer	1.02e-05	0.000329	CcSEcCtD
Vandetanib—Chest pain—Docetaxel—lung cancer	1.02e-05	0.000329	CcSEcCtD
Vandetanib—Nausea—Vinorelbine—lung cancer	1.02e-05	0.000329	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—lung cancer	1.02e-05	0.000328	CcSEcCtD
Vandetanib—Dyspepsia—Paclitaxel—lung cancer	1.02e-05	0.000328	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—lung cancer	1.02e-05	0.000328	CcSEcCtD
Vandetanib—Asthenia—Irinotecan—lung cancer	1.02e-05	0.000327	CcSEcCtD
Vandetanib—Fatigue—Etoposide—lung cancer	1.02e-05	0.000327	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	1.02e-05	0.000327	CcSEcCtD
Vandetanib—Constipation—Etoposide—lung cancer	1.01e-05	0.000325	CcSEcCtD
Vandetanib—Pain—Etoposide—lung cancer	1.01e-05	0.000325	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—lung cancer	1.01e-05	0.000324	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—lung cancer	1.01e-05	0.000324	CcSEcCtD
Vandetanib—Decreased appetite—Paclitaxel—lung cancer	1.01e-05	0.000324	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—lung cancer	1e-05	0.000322	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—lung cancer	1e-05	0.000322	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—lung cancer	1e-05	0.000322	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Paclitaxel—lung cancer	1e-05	0.000321	CcSEcCtD
Vandetanib—Fatigue—Paclitaxel—lung cancer	9.99e-06	0.000321	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—lung cancer	9.96e-06	0.00032	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—lung cancer	9.95e-06	0.00032	CcSEcCtD
Vandetanib—Asthenia—Gemcitabine—lung cancer	9.93e-06	0.000319	CcSEcCtD
Vandetanib—Pain—Paclitaxel—lung cancer	9.91e-06	0.000318	CcSEcCtD
Vandetanib—Constipation—Paclitaxel—lung cancer	9.91e-06	0.000318	CcSEcCtD
Vandetanib—Gefitinib—ALB—lung cancer	9.87e-06	0.00754	CrCbGaD
Vandetanib—Urinary tract disorder—Methotrexate—lung cancer	9.84e-06	0.000316	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—lung cancer	9.84e-06	0.000316	CcSEcCtD
Vandetanib—Oedema—Docetaxel—lung cancer	9.82e-06	0.000315	CcSEcCtD
Vandetanib—Pruritus—Gemcitabine—lung cancer	9.79e-06	0.000315	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—lung cancer	9.76e-06	0.000314	CcSEcCtD
Vandetanib—Infection—Docetaxel—lung cancer	9.75e-06	0.000313	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—lung cancer	9.75e-06	0.000313	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—lung cancer	9.72e-06	0.000312	CcSEcCtD
Vandetanib—Diarrhoea—Irinotecan—lung cancer	9.72e-06	0.000312	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—lung cancer	9.66e-06	0.00031	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—lung cancer	9.66e-06	0.00031	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—lung cancer	9.63e-06	0.000309	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—lung cancer	9.61e-06	0.000309	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—lung cancer	9.61e-06	0.000309	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—lung cancer	9.61e-06	0.000309	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—lung cancer	9.6e-06	0.000308	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—lung cancer	9.54e-06	0.000306	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—lung cancer	9.53e-06	0.000306	CcSEcCtD
Vandetanib—Gastrointestinal pain—Paclitaxel—lung cancer	9.47e-06	0.000304	CcSEcCtD
Vandetanib—Diarrhoea—Gemcitabine—lung cancer	9.47e-06	0.000304	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—lung cancer	9.44e-06	0.000303	CcSEcCtD
Vandetanib—Gefitinib—ABCB1—lung cancer	9.42e-06	0.00719	CrCbGaD
Vandetanib—Erythema multiforme—Methotrexate—lung cancer	9.42e-06	0.000303	CcSEcCtD
Vandetanib—Dizziness—Irinotecan—lung cancer	9.39e-06	0.000302	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—lung cancer	9.37e-06	0.000301	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—lung cancer	9.34e-06	0.0003	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—lung cancer	9.34e-06	0.0003	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—lung cancer	9.34e-06	0.0003	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—lung cancer	9.34e-06	0.0003	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—lung cancer	9.31e-06	0.000299	CcSEcCtD
Vandetanib—Bosutinib—ABCB1—lung cancer	9.27e-06	0.00708	CrCbGaD
Vandetanib—Asthenia—Cisplatin—lung cancer	9.25e-06	0.000297	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—lung cancer	9.24e-06	0.000297	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—lung cancer	9.16e-06	0.000294	CcSEcCtD
Vandetanib—Body temperature increased—Paclitaxel—lung cancer	9.16e-06	0.000294	CcSEcCtD
Vandetanib—Abdominal pain—Paclitaxel—lung cancer	9.16e-06	0.000294	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—lung cancer	9.09e-06	0.000292	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—lung cancer	9.06e-06	0.000291	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—lung cancer	9.04e-06	0.00029	CcSEcCtD
Vandetanib—Vomiting—Irinotecan—lung cancer	9.03e-06	0.00029	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—lung cancer	9.01e-06	0.00029	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—lung cancer	8.98e-06	0.000288	CcSEcCtD
Vandetanib—Rash—Irinotecan—lung cancer	8.96e-06	0.000288	CcSEcCtD
Vandetanib—Dermatitis—Irinotecan—lung cancer	8.95e-06	0.000287	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—lung cancer	8.95e-06	0.000287	CcSEcCtD
Vandetanib—Headache—Irinotecan—lung cancer	8.9e-06	0.000286	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—lung cancer	8.88e-06	0.000285	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—lung cancer	8.82e-06	0.000284	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—lung cancer	8.82e-06	0.000283	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—lung cancer	8.8e-06	0.000283	CcSEcCtD
Vandetanib—Vomiting—Gemcitabine—lung cancer	8.8e-06	0.000283	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—lung cancer	8.78e-06	0.000282	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—lung cancer	8.75e-06	0.000281	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—lung cancer	8.73e-06	0.00028	CcSEcCtD
Vandetanib—Rash—Gemcitabine—lung cancer	8.72e-06	0.00028	CcSEcCtD
Vandetanib—Dermatitis—Gemcitabine—lung cancer	8.72e-06	0.00028	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—lung cancer	8.67e-06	0.000279	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—lung cancer	8.67e-06	0.000279	CcSEcCtD
Vandetanib—Headache—Gemcitabine—lung cancer	8.67e-06	0.000278	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—lung cancer	8.64e-06	0.000278	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—lung cancer	8.62e-06	0.000277	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—lung cancer	8.54e-06	0.000274	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—lung cancer	8.52e-06	0.000274	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—lung cancer	8.49e-06	0.000273	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—lung cancer	8.48e-06	0.000272	CcSEcCtD
Vandetanib—Asthenia—Etoposide—lung cancer	8.48e-06	0.000272	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—lung cancer	8.46e-06	0.000272	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—lung cancer	8.45e-06	0.000272	CcSEcCtD
Vandetanib—Nausea—Irinotecan—lung cancer	8.44e-06	0.000271	CcSEcCtD
Vandetanib—Pain—Docetaxel—lung cancer	8.4e-06	0.00027	CcSEcCtD
Vandetanib—Constipation—Docetaxel—lung cancer	8.4e-06	0.00027	CcSEcCtD
Vandetanib—Pruritus—Etoposide—lung cancer	8.36e-06	0.000269	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—lung cancer	8.31e-06	0.000267	CcSEcCtD
Vandetanib—Asthenia—Paclitaxel—lung cancer	8.31e-06	0.000267	CcSEcCtD
Vandetanib—Nausea—Gemcitabine—lung cancer	8.22e-06	0.000264	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—lung cancer	8.2e-06	0.000263	CcSEcCtD
Vandetanib—Pruritus—Paclitaxel—lung cancer	8.2e-06	0.000263	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—lung cancer	8.17e-06	0.000263	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—lung cancer	8.15e-06	0.000262	CcSEcCtD
Vandetanib—Rash—Cisplatin—lung cancer	8.13e-06	0.000261	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—lung cancer	8.12e-06	0.000261	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—lung cancer	8.08e-06	0.00026	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—lung cancer	8.06e-06	0.000259	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—lung cancer	8.03e-06	0.000258	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—lung cancer	8e-06	0.000257	CcSEcCtD
Vandetanib—Diarrhoea—Paclitaxel—lung cancer	7.93e-06	0.000255	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—lung cancer	7.83e-06	0.000251	CcSEcCtD
Vandetanib—Dizziness—Etoposide—lung cancer	7.81e-06	0.000251	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—lung cancer	7.77e-06	0.00025	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—lung cancer	7.76e-06	0.000249	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—lung cancer	7.76e-06	0.000249	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—lung cancer	7.7e-06	0.000248	CcSEcCtD
Vandetanib—Dizziness—Paclitaxel—lung cancer	7.66e-06	0.000246	CcSEcCtD
Vandetanib—Nausea—Cisplatin—lung cancer	7.66e-06	0.000246	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—lung cancer	7.62e-06	0.000245	CcSEcCtD
Vandetanib—Cough—Methotrexate—lung cancer	7.57e-06	0.000243	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—lung cancer	7.56e-06	0.000243	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—lung cancer	7.51e-06	0.000241	CcSEcCtD
Vandetanib—Vomiting—Etoposide—lung cancer	7.51e-06	0.000241	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—lung cancer	7.51e-06	0.000241	CcSEcCtD
Vandetanib—Rash—Etoposide—lung cancer	7.45e-06	0.000239	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—lung cancer	7.44e-06	0.000239	CcSEcCtD
Vandetanib—Headache—Etoposide—lung cancer	7.4e-06	0.000238	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—lung cancer	7.38e-06	0.000237	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—lung cancer	7.38e-06	0.000237	CcSEcCtD
Vandetanib—Vomiting—Paclitaxel—lung cancer	7.37e-06	0.000237	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—lung cancer	7.35e-06	0.000236	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	7.33e-06	0.000236	CcSEcCtD
Vandetanib—Rash—Paclitaxel—lung cancer	7.3e-06	0.000235	CcSEcCtD
Vandetanib—Dermatitis—Paclitaxel—lung cancer	7.3e-06	0.000234	CcSEcCtD
Vandetanib—Headache—Paclitaxel—lung cancer	7.26e-06	0.000233	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—lung cancer	7.22e-06	0.000232	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—lung cancer	7.08e-06	0.000227	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—lung cancer	7.04e-06	0.000226	CcSEcCtD
Vandetanib—Infection—Methotrexate—lung cancer	7.03e-06	0.000226	CcSEcCtD
Vandetanib—Nausea—Etoposide—lung cancer	7.02e-06	0.000225	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—lung cancer	6.95e-06	0.000223	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—lung cancer	6.94e-06	0.000223	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—lung cancer	6.93e-06	0.000223	CcSEcCtD
Vandetanib—Nausea—Paclitaxel—lung cancer	6.88e-06	0.000221	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—lung cancer	6.87e-06	0.000221	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—lung cancer	6.72e-06	0.000216	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—lung cancer	6.6e-06	0.000212	CcSEcCtD
Vandetanib—Cough—Doxorubicin—lung cancer	6.55e-06	0.000211	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—lung cancer	6.51e-06	0.000209	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—lung cancer	6.49e-06	0.000209	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—lung cancer	6.48e-06	0.000208	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—lung cancer	6.45e-06	0.000207	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—lung cancer	6.4e-06	0.000206	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—lung cancer	6.39e-06	0.000205	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—lung cancer	6.39e-06	0.000205	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—lung cancer	6.37e-06	0.000205	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—lung cancer	6.35e-06	0.000204	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.35e-06	0.000204	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—lung cancer	6.31e-06	0.000203	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—lung cancer	6.25e-06	0.000201	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—lung cancer	6.24e-06	0.000201	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—lung cancer	6.23e-06	0.0002	CcSEcCtD
Vandetanib—Rash—Docetaxel—lung cancer	6.19e-06	0.000199	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—lung cancer	6.18e-06	0.000199	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—lung cancer	6.15e-06	0.000198	CcSEcCtD
Vandetanib—Headache—Docetaxel—lung cancer	6.15e-06	0.000198	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—lung cancer	6.13e-06	0.000197	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—lung cancer	6.11e-06	0.000196	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—lung cancer	6.1e-06	0.000196	CcSEcCtD
Vandetanib—Infection—Doxorubicin—lung cancer	6.09e-06	0.000196	CcSEcCtD
Vandetanib—Pain—Methotrexate—lung cancer	6.05e-06	0.000194	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—lung cancer	6.01e-06	0.000193	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—lung cancer	6e-06	0.000193	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—lung cancer	5.95e-06	0.000191	CcSEcCtD
Vandetanib—Nausea—Docetaxel—lung cancer	5.83e-06	0.000187	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—lung cancer	5.79e-06	0.000186	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—lung cancer	5.59e-06	0.00018	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—lung cancer	5.59e-06	0.00018	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.58e-06	0.000179	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—lung cancer	5.54e-06	0.000178	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—lung cancer	5.5e-06	0.000177	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—lung cancer	5.46e-06	0.000176	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—lung cancer	5.39e-06	0.000173	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—lung cancer	5.33e-06	0.000171	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—lung cancer	5.29e-06	0.00017	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—lung cancer	5.28e-06	0.00017	CcSEcCtD
Vandetanib—Pain—Doxorubicin—lung cancer	5.24e-06	0.000168	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—lung cancer	5.24e-06	0.000168	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—lung cancer	5.08e-06	0.000163	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—lung cancer	5.01e-06	0.000161	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—lung cancer	5.01e-06	0.000161	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—lung cancer	4.84e-06	0.000156	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—lung cancer	4.84e-06	0.000156	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—lung cancer	4.84e-06	0.000156	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—lung cancer	4.68e-06	0.00015	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—lung cancer	4.5e-06	0.000145	CcSEcCtD
Vandetanib—Rash—Methotrexate—lung cancer	4.46e-06	0.000143	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—lung cancer	4.46e-06	0.000143	CcSEcCtD
Vandetanib—Headache—Methotrexate—lung cancer	4.43e-06	0.000142	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—lung cancer	4.4e-06	0.000141	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—lung cancer	4.34e-06	0.000139	CcSEcCtD
Vandetanib—Nausea—Methotrexate—lung cancer	4.2e-06	0.000135	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—lung cancer	4.19e-06	0.000135	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—lung cancer	4.05e-06	0.00013	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—lung cancer	3.9e-06	0.000125	CcSEcCtD
Vandetanib—Rash—Doxorubicin—lung cancer	3.86e-06	0.000124	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—lung cancer	3.86e-06	0.000124	CcSEcCtD
Vandetanib—Headache—Doxorubicin—lung cancer	3.84e-06	0.000123	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—lung cancer	3.64e-06	0.000117	CcSEcCtD
Vandetanib—CYP3A4—Metabolism—CYP2A6—lung cancer	1.52e-07	3.95e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCLC—lung cancer	1.52e-07	3.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—lung cancer	1.52e-07	3.95e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—lung cancer	1.52e-07	3.95e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—lung cancer	1.52e-07	3.93e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—lung cancer	1.51e-07	3.93e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—lung cancer	1.51e-07	3.92e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—lung cancer	1.51e-07	3.92e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—lung cancer	1.51e-07	3.92e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—lung cancer	1.51e-07	3.91e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—lung cancer	1.51e-07	3.91e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—lung cancer	1.51e-07	3.91e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—lung cancer	1.51e-07	3.9e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—lung cancer	1.5e-07	3.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—lung cancer	1.5e-07	3.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—lung cancer	1.5e-07	3.9e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—lung cancer	1.5e-07	3.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—lung cancer	1.49e-07	3.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—lung cancer	1.49e-07	3.86e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—lung cancer	1.49e-07	3.85e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—lung cancer	1.48e-07	3.85e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RAF1—lung cancer	1.48e-07	3.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAP2K1—lung cancer	1.48e-07	3.84e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—lung cancer	1.48e-07	3.84e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—lung cancer	1.47e-07	3.82e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—lung cancer	1.47e-07	3.82e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—lung cancer	1.47e-07	3.81e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—lung cancer	1.47e-07	3.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—lung cancer	1.47e-07	3.8e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—lung cancer	1.46e-07	3.8e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—lung cancer	1.46e-07	3.78e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—lung cancer	1.46e-07	3.77e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—lung cancer	1.45e-07	3.77e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—lung cancer	1.45e-07	3.77e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—lung cancer	1.45e-07	3.77e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—lung cancer	1.45e-07	3.76e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—lung cancer	1.45e-07	3.75e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—lung cancer	1.45e-07	3.75e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—lung cancer	1.45e-07	3.75e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—lung cancer	1.45e-07	3.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO1—lung cancer	1.44e-07	3.75e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—lung cancer	1.44e-07	3.74e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—lung cancer	1.44e-07	3.74e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—lung cancer	1.44e-07	3.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—lung cancer	1.43e-07	3.72e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—lung cancer	1.43e-07	3.72e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—lung cancer	1.42e-07	3.69e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.42e-07	3.67e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—lung cancer	1.42e-07	3.67e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—lung cancer	1.42e-07	3.67e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—lung cancer	1.41e-07	3.67e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—lung cancer	1.41e-07	3.66e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—lung cancer	1.41e-07	3.65e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—lung cancer	1.4e-07	3.63e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—lung cancer	1.4e-07	3.62e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—lung cancer	1.39e-07	3.62e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—lung cancer	1.39e-07	3.62e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—lung cancer	1.39e-07	3.61e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—lung cancer	1.39e-07	3.61e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—lung cancer	1.39e-07	3.61e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—lung cancer	1.39e-07	3.61e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—lung cancer	1.39e-07	3.61e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—lung cancer	1.39e-07	3.6e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—lung cancer	1.39e-07	3.6e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—lung cancer	1.38e-07	3.59e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—lung cancer	1.38e-07	3.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—lung cancer	1.38e-07	3.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—lung cancer	1.38e-07	3.58e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—lung cancer	1.38e-07	3.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—lung cancer	1.37e-07	3.56e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—lung cancer	1.37e-07	3.56e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—lung cancer	1.37e-07	3.54e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—lung cancer	1.37e-07	3.54e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—lung cancer	1.36e-07	3.53e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—lung cancer	1.36e-07	3.53e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—lung cancer	1.36e-07	3.52e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—lung cancer	1.36e-07	3.52e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—lung cancer	1.35e-07	3.51e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—lung cancer	1.35e-07	3.5e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—lung cancer	1.35e-07	3.5e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—lung cancer	1.35e-07	3.49e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—lung cancer	1.34e-07	3.49e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—lung cancer	1.34e-07	3.49e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—lung cancer	1.34e-07	3.48e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—lung cancer	1.34e-07	3.48e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—lung cancer	1.34e-07	3.48e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—lung cancer	1.34e-07	3.47e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—lung cancer	1.34e-07	3.46e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	1.33e-07	3.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—lung cancer	1.33e-07	3.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—lung cancer	1.33e-07	3.45e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—lung cancer	1.32e-07	3.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—lung cancer	1.32e-07	3.42e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—lung cancer	1.32e-07	3.41e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—lung cancer	1.31e-07	3.41e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RAF1—lung cancer	1.31e-07	3.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—lung cancer	1.31e-07	3.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—lung cancer	1.31e-07	3.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—lung cancer	1.31e-07	3.39e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—lung cancer	1.3e-07	3.38e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—lung cancer	1.3e-07	3.37e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—lung cancer	1.3e-07	3.37e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—lung cancer	1.3e-07	3.37e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—lung cancer	1.3e-07	3.36e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2E1—lung cancer	1.3e-07	3.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—lung cancer	1.3e-07	3.36e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—lung cancer	1.29e-07	3.35e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—lung cancer	1.29e-07	3.33e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—lung cancer	1.29e-07	3.33e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—lung cancer	1.28e-07	3.33e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—lung cancer	1.28e-07	3.33e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—lung cancer	1.28e-07	3.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—lung cancer	1.28e-07	3.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—lung cancer	1.28e-07	3.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—lung cancer	1.28e-07	3.32e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—lung cancer	1.28e-07	3.32e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—lung cancer	1.27e-07	3.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—lung cancer	1.27e-07	3.29e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—lung cancer	1.27e-07	3.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—lung cancer	1.27e-07	3.28e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—lung cancer	1.26e-07	3.28e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—lung cancer	1.26e-07	3.27e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—lung cancer	1.26e-07	3.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—lung cancer	1.25e-07	3.25e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—lung cancer	1.25e-07	3.25e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CREBBP—lung cancer	1.25e-07	3.25e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—lung cancer	1.25e-07	3.24e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—lung cancer	1.25e-07	3.24e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—lung cancer	1.24e-07	3.22e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—lung cancer	1.24e-07	3.21e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—lung cancer	1.24e-07	3.21e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—lung cancer	1.23e-07	3.19e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—lung cancer	1.23e-07	3.19e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—lung cancer	1.22e-07	3.17e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—lung cancer	1.22e-07	3.17e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—lung cancer	1.21e-07	3.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—lung cancer	1.21e-07	3.14e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—lung cancer	1.21e-07	3.13e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—lung cancer	1.21e-07	3.13e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—lung cancer	1.2e-07	3.12e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—lung cancer	1.2e-07	3.1e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—lung cancer	1.19e-07	3.09e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—lung cancer	1.19e-07	3.08e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—lung cancer	1.18e-07	3.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—lung cancer	1.18e-07	3.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—lung cancer	1.18e-07	3.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—lung cancer	1.17e-07	3.04e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—lung cancer	1.17e-07	3.04e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—lung cancer	1.17e-07	3.02e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—lung cancer	1.16e-07	3.01e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—lung cancer	1.16e-07	3.01e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—lung cancer	1.16e-07	3.01e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—lung cancer	1.16e-07	3e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—lung cancer	1.16e-07	3e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—lung cancer	1.16e-07	3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STK11—lung cancer	1.15e-07	2.99e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—lung cancer	1.15e-07	2.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—lung cancer	1.15e-07	2.98e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—lung cancer	1.15e-07	2.97e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—lung cancer	1.13e-07	2.94e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—lung cancer	1.13e-07	2.93e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—lung cancer	1.12e-07	2.9e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—lung cancer	1.12e-07	2.9e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—lung cancer	1.12e-07	2.89e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—lung cancer	1.12e-07	2.89e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—lung cancer	1.12e-07	2.89e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—lung cancer	1.12e-07	2.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—lung cancer	1.11e-07	2.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—lung cancer	1.11e-07	2.88e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—lung cancer	1.11e-07	2.88e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—lung cancer	1.11e-07	2.87e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	1.1e-07	2.85e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—lung cancer	1.08e-07	2.8e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—lung cancer	1.08e-07	2.79e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—lung cancer	1.07e-07	2.78e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—lung cancer	1.07e-07	2.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—lung cancer	1.07e-07	2.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—lung cancer	1.07e-07	2.77e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—lung cancer	1.06e-07	2.76e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—lung cancer	1.06e-07	2.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—lung cancer	1.06e-07	2.74e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—lung cancer	1.04e-07	2.7e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAT—lung cancer	1.04e-07	2.7e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—lung cancer	1.04e-07	2.7e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—lung cancer	1.04e-07	2.68e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—lung cancer	1.03e-07	2.68e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—lung cancer	1.03e-07	2.67e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—lung cancer	1.03e-07	2.66e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—lung cancer	1.03e-07	2.66e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—lung cancer	1.02e-07	2.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—lung cancer	1.02e-07	2.64e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—lung cancer	1.02e-07	2.64e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—lung cancer	1.01e-07	2.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—lung cancer	1e-07	2.59e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—lung cancer	9.97e-08	2.59e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—lung cancer	9.96e-08	2.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—lung cancer	9.94e-08	2.58e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—lung cancer	9.91e-08	2.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—lung cancer	9.88e-08	2.56e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—lung cancer	9.88e-08	2.56e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—lung cancer	9.87e-08	2.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—lung cancer	9.82e-08	2.55e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—lung cancer	9.81e-08	2.54e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—lung cancer	9.74e-08	2.53e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—lung cancer	9.61e-08	2.49e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—lung cancer	9.54e-08	2.47e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—lung cancer	9.49e-08	2.46e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—lung cancer	9.46e-08	2.45e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—lung cancer	9.39e-08	2.43e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—lung cancer	9.31e-08	2.41e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—lung cancer	9.23e-08	2.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—lung cancer	9.2e-08	2.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—lung cancer	9.16e-08	2.38e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—lung cancer	9.12e-08	2.36e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—lung cancer	9e-08	2.33e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—lung cancer	8.98e-08	2.33e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—lung cancer	8.94e-08	2.32e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—lung cancer	8.86e-08	2.3e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—lung cancer	8.83e-08	2.29e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—lung cancer	8.8e-08	2.28e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—lung cancer	8.66e-08	2.25e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—lung cancer	8.54e-08	2.21e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—lung cancer	8.53e-08	2.21e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—lung cancer	8.5e-08	2.21e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—lung cancer	8.47e-08	2.2e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—lung cancer	8.35e-08	2.17e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—lung cancer	8.17e-08	2.12e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—lung cancer	8.11e-08	2.1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—lung cancer	7.99e-08	2.07e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—lung cancer	7.82e-08	2.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—lung cancer	7.81e-08	2.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—lung cancer	7.56e-08	1.96e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—lung cancer	7.48e-08	1.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—lung cancer	7.29e-08	1.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—lung cancer	7.23e-08	1.87e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—lung cancer	7.21e-08	1.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—lung cancer	6.94e-08	1.8e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—lung cancer	6.92e-08	1.79e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CREBBP—lung cancer	6.76e-08	1.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—lung cancer	6.41e-08	1.66e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—lung cancer	6.38e-08	1.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—lung cancer	6.33e-08	1.64e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—lung cancer	6.31e-08	1.64e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—lung cancer	5.59e-08	1.45e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—lung cancer	5.54e-08	1.44e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—lung cancer	5.15e-08	1.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—lung cancer	4.83e-08	1.25e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—lung cancer	4.6e-08	1.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—lung cancer	3.41e-08	8.83e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—lung cancer	2.78e-08	7.22e-07	CbGpPWpGaD
